Sanofi and GSK have jointly developed a next-generation COVID-19 booster vaccine candidate, based on Sanofi’s recombinant Beta variant antigen and combined with GSK’s pandemic adjuvant. Both have served as established vaccine platforms that have proven successful against influenza.
Ook interessant voor je
